Showing 5 posts of 5 posts found.

Santhera closes exclusive license agreement with Catalyst Pharmaceuticals for Vamorolone

July 19, 2023
Medical Communications License Agreement, Musculo-skeletal disorder, Vamorolone, catalyst, santhera

Santhera Pharmaceuticals has announced the closing of its exclusive North American license agreement for vamorolone with Catalyst Pharmaceuticals. The agreement …

Santhera and Catalyst Pharmaceuticals sign $231m license and collaboration deal

June 20, 2023
Medical Communications Catalyst Pharmaceuticals, Rare Diseases, Vamorolone, licence and collaboration, santhera

Swiss specialty pharmaceutical company Santhera and US-based biopharmaceutical company Catalyst Pharmaceuticals have announced that they have signed an exclusive license …

Santhera ‘surprised’ by European rejection of DMD drug

September 18, 2017
Sales and Marketing Duchenne Muscular Dystrophy, biotech, drugs, pharma, pharmaceutical, santhera

Santhera Pharmaceutical has announced the EMA’s CHMP rejected its treatment for Duchenne muscular dystrophy (DMD) but revealed that it planned …


Shares drop at Santhera after FDA requires more trial data DMD drug

July 15, 2016
Medical Communications, Research and Development Duchenne Muscular Dystrophy, FDA, santhera

Santhera Pharmaceuticals (SIX: SANN) has seen shares fall as much as 38% after the US Food and Drug Administration (FDA) …

Latest content